Revelation Therapeutics Secures FDA Alignment for Single-Study Approval Pathway of Gemini in Acute Kidney Injury

Revelation Therapeutics Inc. (NASDAQ: RVMD) announced on January 23, 2026, that the U.S. Food and Drug Administration (FDA) has aligned with its proposed single-study approval pathway for Gemini, a novel treatment targeting acute kidney injury. The company stated that this regulatory alignment significantly streamlines the development process, potentially accelerating market access for the therapy. Gemini, currently in Phase II trials, aims to address a critical unmet need in acute kidney injury management. Revelation anticipates submitting pivotal data from the single study to the FDA by mid-2027. Analysts note that successful approval could position Gemini as a leading therapeutic option, with potential revenue projections exceeding $500 million annually upon launch. Shares of RVMD traded at $18.50 prior to the announcement, reflecting investor optimism about the milestone.